Current Hypertension Reports

, Volume 11, Issue 5, pp 345–353 | Cite as

Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy



Proteinuria is both a marker and a mediator of progressive renal damage; higher levels are associated with greater cardiovascular and renal risk. At normal and low levels of proteinuria (in the microalbuminuria range), the rate of hard renal events (dialysis and doubling of creatinine) is much lower than the mortality rate. At higher levels of proteinuria, the renal event rate surpasses the mortality rate. In the overt nephropathy range (proteinuria > 0.5 g/L), patients who achieve lower proteinuria with therapy have improved hard renal outcomes, but this result has not been demonstrated in the microalbuminuria range. For patients with more severe overt nephropathy, there is a basic rationale for additional blockade of the renin-angiotensin-aldosterone system (RAAS). Dual blockade of this system and supramaximal dosing with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) have been demonstrated to reduce proteinuria in these patients more than therapy using the maximum recommended doses of these agents. However, evidence that dual blockade provides additional benefits for hard renal and cardiovascular outcomes is lacking, and only one study shows a benefit for supramaximal dosing. Both treatment strategies increase the risk for complications such as hyperkalemia. Therapy for patients with nephropathy should include treatment with the maximum recommended doses of an ACE inhibitor or ARB in addition to lowering blood pressure to target. For patients with overt nephropathy, more research is required on the role of dual therapy or supramaximal dosing to reduce hard renal and cardiovascular outcomes. Practitioners using either of these strategies to manage proteinuria should monitor their patients carefully.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Ruggenenti P, Remuzzi G: Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health. Clin J Am Soc Nephrol 2007, 2:146–150.PubMedCrossRefGoogle Scholar
  2. 2.
    Hillege HL, Fidler V, Diercks GF, et al.: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002, 106:1777–1782.PubMedCrossRefGoogle Scholar
  3. 3.
    Forman JP, Brenner BM: ’Hypertension’ and ‘microalbuminuria’: the bell tolls for thee. Kidney Int 2006, 69:22–28.PubMedCrossRefGoogle Scholar
  4. 4.
    Ruggenenti P, Remuzzi G: Time to abandon microalbuminuria? Kidney Int 2006, 70:1214–1222.PubMedCrossRefGoogle Scholar
  5. 5.
    Cravedi P, Ruggenenti P, Remuzzi G: Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep 2009, 11:118–124.PubMedCrossRefGoogle Scholar
  6. 6.
    de Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309–2320.PubMedCrossRefGoogle Scholar
  7. 7.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.PubMedCrossRefGoogle Scholar
  8. 8.
    Bjorck S, Mulec H, Johnsen SA, et al.: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304:339–343.PubMedCrossRefGoogle Scholar
  9. 9.
    The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997, 349:1857–1863.CrossRefGoogle Scholar
  10. 10.
    Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.PubMedGoogle Scholar
  11. 11.
    Jafar TH, Schmid CH, Landa M, et al.: Angiotensinconverting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73–87.PubMedGoogle Scholar
  12. 12.
    Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244–252.PubMedGoogle Scholar
  13. 13.
    Jafar TH, Stark PC, Schmid CH, et al.: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131–1140.PubMedCrossRefGoogle Scholar
  14. 14.
    Kent DM, Jafar TH, Hayward RA, et al.: Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007, 18:1959–1965.PubMedCrossRefGoogle Scholar
  15. 15.
    Balamuthusamy S, Srinivasan L, Verma M, et al.: Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008, 155:791–805.PubMedCrossRefGoogle Scholar
  16. 16.
    Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026–2033.PubMedCrossRefGoogle Scholar
  17. 17.
    Mann JF, Gerstein HC, Yi QL, et al.: Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003, 42:936–942.PubMedCrossRefGoogle Scholar
  18. 18.
    Patel A, MacMahon S, Chalmers J, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829–840.PubMedCrossRefGoogle Scholar
  19. 19.
    The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.CrossRefGoogle Scholar
  20. 20.
    Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.PubMedCrossRefGoogle Scholar
  21. 21.
    Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.PubMedCrossRefGoogle Scholar
  22. 22.
    Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547–553.PubMedCrossRefGoogle Scholar
  23. 23.
    Doulton TW, He FJ, MacGregor GA: Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45:880–886.PubMedCrossRefGoogle Scholar
  24. 24.
    Catapano F, Chiodini P, De Nicola L, et al.: Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 2008, 52:475–485.PubMedCrossRefGoogle Scholar
  25. 25.
    Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799–812.PubMedCrossRefGoogle Scholar
  26. 26.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.PubMedCrossRefGoogle Scholar
  27. 27.
    Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  28. 28.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.PubMedCrossRefGoogle Scholar
  29. 29.
    Phillips CO, Kashani A, Ko DK, et al.: Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007, 167:1930–1936.PubMedCrossRefGoogle Scholar
  30. 30.
    Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543–551.PubMedCrossRefGoogle Scholar
  31. 31.
    Brenner BM, Lawler EV, Mackenzie HS: The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996, 49:1774–1777.PubMedCrossRefGoogle Scholar
  32. 32.
    Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003, 93:3–13.CrossRefGoogle Scholar
  33. 33.
    Abbate M, Zoja C, Morigi M, et al.: Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol 2002, 161:2179–2193.PubMedGoogle Scholar
  34. 34.
    Iwano M, Kubo A, Nishino T, et al.: Quantification of glomerular TGF-[beta]1 mRNA in patients with diabetes mellitus. Kidney Int 1996, 49:1120–1126.PubMedCrossRefGoogle Scholar
  35. 35.
    Mezzano S, Droguett A, Burgos ME, et al.: Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 2003, S64–S70.Google Scholar
  36. 36.
    Langham RG, Kelly DJ, Gow RM, et al.: Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition. Diabetes Care 2006, 29:2670–2675.PubMedCrossRefGoogle Scholar
  37. 37.
    Parving HH, Lehnert H, Brörhner-Mortensen J, et al.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.PubMedCrossRefGoogle Scholar
  38. 38.
    Rossing K, Schjoedt KJ, Jensen BR, et al.: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005, 68:1190–1198.PubMedCrossRefGoogle Scholar
  39. 39.
    Hollenberg NK, Parving HH, Viberti G, et al.: Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007, 25:1921–1926.PubMedCrossRefGoogle Scholar
  40. 40.
    Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002, 17:1019–1024.PubMedCrossRefGoogle Scholar
  41. 41.
    Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874–1880.PubMedCrossRefGoogle Scholar
  42. 42.
    Schjoedt KJ, Jacobsen P, Rossing K, et al.: Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone. Horm Metab Res 2005, 37(Suppl 1):4–8.CrossRefGoogle Scholar
  43. 43.
    Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.PubMedCrossRefGoogle Scholar
  44. 44.
    Tutuncu NB, Gurlek A, Gedik O: Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 2001, 38:157–161.PubMedCrossRefGoogle Scholar
  45. 45.
    Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003, 26:2268–2274.PubMedCrossRefGoogle Scholar
  46. 46.
    Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48.PubMedGoogle Scholar
  47. 47.
    Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124.PubMedCrossRefGoogle Scholar
  48. 48.
    Kunz R, Wolbers M, Glass T, Mann JF: The COOPERATE trial: a letter of concern. Lancet 2008, 371:1575–1576.PubMedCrossRefGoogle Scholar
  49. 49.
    Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199–211.PubMedCrossRefGoogle Scholar
  50. 50.
    Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940–951.PubMedCrossRefGoogle Scholar
  51. 51.
    Rossing K, Schjoedt KJ, Smidt UM, et al.: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005, 28:2106–2112.PubMedCrossRefGoogle Scholar
  52. 52.
    Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.PubMedCrossRefGoogle Scholar
  53. 53.
    Hou FF, Xie D, Zhang X, et al.: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007, 18:1889–1898.PubMedCrossRefGoogle Scholar
  54. 54.
    Burgess E, Muirhead N, René de Cotret P, et al.: Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009, 20:893–900.PubMedCrossRefGoogle Scholar
  55. 55.
    de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921–927.PubMedCrossRefGoogle Scholar
  56. 56.
    Hunsicker LG, Atkins RC, Lewis JB, et al.: Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004, S99–S101.Google Scholar
  57. 57.
    Gerstein HC, Mann JF, Yi Q, et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421–426.PubMedCrossRefGoogle Scholar
  58. 58.
    Ibsen H, Wachtell K, Olsen MH, et al.: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004, 22:1805–1811.PubMedCrossRefGoogle Scholar
  59. 59.
    Adler AI, Stevens RJ, Manley SE, et al.: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225–232.PubMedCrossRefGoogle Scholar
  60. 60.
    Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Sunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations